Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
Thalidomide-o-PEG2-acid is an E3 ligase ligand-linker conjugate designed for use in targeted protein degradation via PROTAC technology. This compound incorporates a thalidomide-derived cereblon ligand, facilitating the ubiquitination and subsequent proteasomal degradation of target proteins. It is valuable in research applications aimed at understanding protein regulation and exploring therapeutic strategies for various diseases. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-CO is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This reagent is designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs), aiding in targeted protein degradation studies. Its specific interactions facilitate the investigation of E3 ligase-mediated pathways, making it valuable for research applications in drug discovery and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG5-tosyl is an E3 ligase ligand-linker conjugate that utilizes a Thalidomide-derived cereblon ligand in combination with a 4-unit polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC technology, facilitating the recruitment of E3 ligases to target proteins for ubiquitination and subsequent degradation. Thalidomide-O-PEG5-tosyl demonstrates reactivity with nucleophiles, including amine and hydroxy-containing molecules, making it a valuable tool for researchers studying targeted protein degradation and related pathways. -
E3 Ligase Ligand-Linker Conjugate
Dimethyl 3-hydroxyphthalate-amido-C4-N3 is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This compound serves as a crucial component in the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation. It facilitates the recruitment of E3 ligases, which are essential for the ubiquitination process, making it valuable for research in targeted therapy and protein regulation studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-3,8-diazabicyclo[3.2.1]octane-Boc is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand and a linker structure, facilitating the synthesis of PROTACs. This compound is instrumental in targeted protein degradation research, enabling precise modulation of protein levels within cells. Its unique design allows for effective recruitment of E3 ligases in various biological systems, making it a valuable tool for exploring protein homeostasis and therapeutic applications in diseases. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C6-Br is an E3 ligase ligand-linker conjugate that utilizes a thalidomide-derived CRBN ligand, designed for applications in PROTAC technology. This compound is intended for the selective degradation of target proteins by facilitating the formation of protein degrader molecules, such as PROTAC EZH2 Degrader-12. Its unique structure allows for the targeted modulation of protein levels, making it a valuable tool for research into targeted protein degradation and related therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-cyclohexane-C-COOH is a conjugate that serves as an E3 ligase ligand-linker. This compound features a cereblon (CRBN)-based ligand combined with a cyclohexane linker, facilitating the synthesis of proteolysis-targeting chimeras (PROTACs). It is employed in research to explore targeted protein degradation mechanisms and to develop innovative therapeutic strategies against various diseases. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C4-Br is an E3 ligase ligand-linker conjugate derived from thalidomide, specifically targeting the cereblon (CRBN) E3 ubiquitin ligase. This compound facilitates the formation of PROTACs, enabling targeted protein degradation, with applications in cancer research and therapeutic development. Thalidomide-4-O-C4-Br can be utilized to generate conjugates such as PROTAC EZH2 Degrader-10, which are designed to selectively degrade specific proteins of interest in a cellular context. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-C-azetidine TFA is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand integrated with a linker moiety. This compound is designed for the synthesis of PROteolysis TArgeting Chimeras (PROTACs), facilitating targeted protein degradation pathways. Its application in research primarily includes the exploration of E3 ligase-mediated ubiquitination processes and the development of targeted therapies in drug discovery. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C4-N3 is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand and an optimized linker moiety. This compound is designed to facilitate the synthesis of proteolysis-targeting chimeras (PROTACs), enabling selective degradation of target proteins. Its versatile applications in chemical biology and targeted protein modulation make it a valuable tool for research in drug discovery and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand 63-N-CH2-Ph-O-CH3 is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand and a flexible linker. This compound is designed for the synthesis of PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation. Its unique structure supports the recruitment of E3 ligases to target proteins, enabling efficient modulation of protein levels in various research applications, including cancer therapy and cellular signaling studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-C-piperazine TFA is an E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTACs. This compound features a cereblon (CRBN)-based ligand, enabling targeted ubiquitination and proteasomal degradation of specific proteins. Its unique structure facilitates the development of bifunctional constructs for targeted protein modulation in therapeutic research applications. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-O-piperidin is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand and a linker region. This compound is designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling selective degradation of target proteins via the ubiquitin-proteasome system. Its application in chemical biology facilitates targeted protein modulation and offers insights into protein function and disease mechanisms. -
Antiproliferative
Pomalidomide-C2-amide-C5-azide is an E3 ligase linker conjugate that targets selected proteins for ubiquitination and degradation via the PROTAC (proteolysis-targeting chimera) approach. This compound demonstrates notable antiproliferative activity and can be utilized in research applications focused on CDK9 modulation. Its design allows for the synthesis of potent PROTAC molecules, advancing studies in targeted protein degradation and cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
(S)-Deoxy-thalidomide-Pip-3-hydroxypropanoic acid hydrochloride is an E3 ligase ligand-linker conjugate designed to engage cereblon (CRBN) for targeted protein degradation. This compound facilitates the synthesis of PROTACs (proteolysis-targeting chimeras), making it a valuable tool for exploring targeted therapies in cancer and other diseases. Its unique structure enhances the selective degradation of specific proteins, aiding in the study of protein dynamics and function within cellular systems. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-CO-piperazine hydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates a cereblon (CRBN)-based ligand and a piperazine linker, facilitating the synthesis of PROTACs (proteolysis-targeting chimeras). It serves as a valuable tool for researchers investigating innovative therapeutic strategies through modulation of protein levels via the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperazine hydrochloride is an E3 ligase ligand-linker conjugate targeting cereblon (CRBN). This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling the selective degradation of target proteins. Its utility in drug development and research highlights its potential for modulating protein levels in various cellular contexts. -
Conjugate Of VHL Ligand And Linker
(S,R,S)-AHPC-Me-CO-C4-COOH is a conjugate of the E3 ligase VHL ligand and a linker. This compound facilitates the synthesis of PROTAC ERα Degrader-12, a highly selective degrader targeting estrogen receptor alpha (ERα). It serves as a valuable tool for research applications focusing on protein degradation mechanisms and targeted therapy development in hormone-responsive cancers. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide 4'-alkylC2-azide is an E3 ligase ligand-linker conjugate that incorporates a Pomalidomide-based cereblon (CRBN) ligand. This reagent is designed for use in synthesizing proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. Its selective binding to E3 ligases enables the development of innovative therapeutic strategies in cellular biology and drug discovery research. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C8-Br is an E3 ligase ligand-linker conjugate that integrates the Thalidomide-derived CRBN ligand with a linear linker designed for PROTAC applications. This reagent facilitates the targeted degradation of proteins, exemplified by its use in the synthesis of PROTAC EZH2 Degrader-15. Thalidomide-4-O-C8-Br is an essential tool for researchers exploring protein regulation and degradation pathways in cellular processes. -
E3 Ligase Ligand-Linker Conjugate
6-(2,6-Dioxopiperidin-3-yl)-2-(piperazin-1-yl)-5H-pyrrolo[3,4-d]pyrimidine-5,7(6H)-dione hydrochloride is a ligand-linker conjugate targeting E3 ligases, specifically designed for the synthesis of PROTACs. It features a CRBN-based ligand that facilitates targeted degradation of intracellular proteins. This compound is essential for researchers exploring targeted therapeutic strategies and studying the role of protein degradation in cellular processes. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-Amide-PEG2-C2-NH2 is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTACs, specifically targeting the degradation of PI3K/110β. This compound facilitates targeted protein degradation by enhancing the recruitment of E3 ligases to specific substrates, enabling the selective modulation of protein levels within cells. Its utilization expands research applications in cancer biology and other areas where protein degradation plays a critical role. -
E3 Ligase Ligand-Linker Conjugate
3-Azathalidomide-piperazine is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand alongside a versatile linker. This compound is primarily utilized in the synthesis of PROTACs (Proteolysis Targeting Chimeras), facilitating targeted protein degradation in research applications. Its effectiveness in modulating protein interactions makes it a valuable tool for studying various cellular processes and disease mechanisms. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-6-F-5-Pip-COOH is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN) ligand for targeted protein degradation. This compound is designed for the synthesis of PROTACs (proteolysis-targeting chimeras), facilitating precise modulation of protein levels in cellular systems. It is a valuable tool for researchers studying targeted therapeutics and protein degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Pip-CH2-piperazine is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This compound facilitates the synthesis of PROTAC (proteolysis-targeting chimeras), enabling targeted degradation of specific proteins within cellular contexts. Its application in chemical biology allows for the exploration of novel therapeutic strategies by modulating protein levels and functions. -
E3 ligase ligand-Linker Conjugate
(S,R,S,R)-AHPC-Me-CO-C7-N3 is a synthesized E3 ligase ligand-linker conjugate that targets the VHL E3 ligase, which plays a crucial role in cellular protein degradation. This compound facilitates the formation of PROTACs, such as the EZH2 Degrader-28, by linking to specific ligands for protein degradation studies. Its application in PROTAC technology makes it valuable for researchers investigating targeted protein modulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-C3-COOH TFA functions as an E3 ligase ligand-linker conjugate, incorporating a CRBN-based ligand and a flexible linker. This compound serves as a valuable building block for synthesizing PROTACs (Proteolysis Targeting Chimeras). It enables targeted protein degradation, thus facilitating the study of protein functions and interactions in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-C-PEG5-amine hydrochloride functions as an E3 ligase ligand-linker conjugate, incorporating a VHL ligand with a (S,R,S)-AHPC-based linker. This compound is designed for use in PROTAC synthesis, facilitating targeted protein degradation in various research applications. Its unique structure allows for the selective recruitment of E3 ligases, making it valuable for studies in protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
(S)-Thalidomide-piperazin besylate is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs) and is significant in research focused on targeted protein degradation. Its unique structure enables selective interaction with E3 ligases, offering valuable insights into protein regulation processes in cellular environments. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-C-piperidin hydrochloride is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand. This compound is used in the synthesis of proteolysis-targeting chimeras (PROTACs), which harness the protein degradation machinery to selectively target proteins for ubiquitin-mediated degradation. Its application is pivotal in studying protein regulation and discovery of novel therapeutic strategies in various diseases. -
E3 ligase ligand-Linker Conjugate
(4R,5S)-Nutlin carboxylic acid-NHC2-PEG2-N3 is an E3 ligase ligand-linker conjugate designed for applications in PROTAC (proteolysis targeting chimera) technology. This compound features the (4R,5S)-Nutlin carboxylic acid, a potent MDM2 inhibitor, facilitating targeted degradation of proteins by linking to an E3 ligase. It is essential for developing PROTACs aimed at directing specific therapeutic pathways for proteins such as EZH2. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-(1-(3-azetidinylmethyl)piperazine) is an E3 ligase ligand-linker conjugate designed for targeted protein degradation via the PROTAC (proteolysis-targeting chimera) platform. This compound features a CRBN-based ligand that facilitates the recruitment of E3 ubiquitin ligase, enabling selective degradation of target proteins. It is a valuable tool for researchers investigating protein regulation, cellular pathways, and therapeutic strategies in drug discovery and development. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-C-piperazine hydrochloride is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand and a versatile linker. This compound serves as a critical component in the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation. It is suitable for research applications focused on protein regulation and therapeutic development in oncology and other fields. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-C-piperidin is an E3 ligase ligand-linker conjugate that includes a CRBN-based ligand. This compound is designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation. It serves as a versatile tool in drug discovery and basic research aimed at modulating protein levels within biological systems. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-C6-Br is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation. This compound plays a crucial role in the synthesis of PROTAC EGFR degrader 9, enabling selective degradation of the epidermal growth factor receptor (EGFR). Its innovative design allows for precise modulation of protein levels, making it valuable in studies focused on therapeutic approaches for cancer and other diseases linked to EGFR dysregulation. -
E3 Ligase Ligand-linker Conjugate
Lenalidomide-acetylene-C3-MsO is an E3 ligase ligand-linker conjugate designed for the synthesis of specific drug conjugates, such as SIAIS039. This compound enables targeted protein degradation through the activation of the ubiquitin-proteasome system. Its utility in research encompasses the investigation of protein interactions and the development of novel therapeutic strategies in cellular models. -
E3 Ligase Ligand-Linker Conjugate
Dihydrouracil-Ph-piperazine-Boc is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a CRBN-based ligand that facilitates selective recruitment of E3 ligases, enabling the synthesis of PROTACs (proteolysis-targeting chimeras). It serves as a valuable tool for researchers exploring degradation-based therapies and the modulation of cellular protein levels. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-5-piperazine-azetidine is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand attached to a versatile linker. This compound is designed to facilitate the synthesis of PROTACs (proteolysis targeting chimeras), enabling targeted degradation of specific proteins within cellular systems. Key applications include the investigation of protein function and the development of novel therapeutic strategies for diseases associated with dysregulated protein levels. -
E3 Ligase Ligand-Linker Conjugate
3-(1-Oxo-5-(3,9-diazaspiro[5.5]undecan-3-yl)isoindolin-2-yl)piperidine-2,6-dione is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates a CRBN-based ligand, enabling the synthesis of PROTAC (Proteolysis Targeting Chimeras) for selective protein modulation. It serves as a critical tool in chemical biology for studying protein function and therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
(S)-Phthalimidinoglutarimide-6-piperazine is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound serves as a key component in the synthesis of PROTAC SMARCA2 degrader-35, facilitating the selective degradation of the SMARCA2 protein. Its role in research underscores its potential for advancing studies in targeted therapeutics and proteostasis modulation. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-azetidine hydrochloride is an E3 ligase ligand-linker conjugate that utilizes a cereblon (CRBN)-based ligand in conjunction with a linker moiety. This compound facilitates the synthesis of PROTACs (proteolysis-targeting chimeras), which can selectively target and degrade specific proteins within cellular systems. Its application in drug discovery and development enhances the understanding of protein regulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG2-NHS ester is an E3 ligase ligand-linker conjugate that incorporates thalidomide-derived cereblon ligands with a PEG linker, facilitating targeted protein degradation via PROTAC technology. This compound is designed for use in research applications involving ubiquitin-proteasome system studies, enabling the modulation of protein levels in a cellular context. Its unique properties make it suitable for exploring therapeutics that can selectively eliminate disease-associated proteins. -
E3 Ligase Ligand-Linker Conjugate
(S)-Deoxy-thalidomide-(R)-pyrrolidine-3-carbaldehyde is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This compound is instrumental in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating targeted degradation of specific proteins within cellular systems. Its unique structure enables efficient recruitment of E3 ligases, making it essential for studies in targeted protein degradation and drug development. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-Pip hydrochloride is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN) ligand and a linker moiety. This compound is designed for the synthesis of proteolysis-targeting chimeras (PROTACs), enabling targeted protein degradation. Its effective engagement with E3 ligases facilitates the selective modulation of protein levels, making it valuable for research in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
DGY-02-126-O-C-COOH is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand and a suitable linker. This compound facilitates the synthesis of PROTAC (Proteolysis Targeting Chimera) molecules, which are instrumental in targeted protein degradation research. Its unique structure supports the development of innovative therapeutic strategies by modulating protein interactions within cellular systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-tert-butyl formate is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand, facilitating targeted protein degradation through the PROTAC (Proteolysis Targeting Chimera) approach. This compound acts by engaging E3 ligases, promoting ubiquitination and subsequent proteasomal degradation of target proteins. It is valuable for research applications involving protein regulation, cellular signaling, and the development of novel therapeutic strategies in various disease contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-C3-NH2 hydrochloride serves as an E3 ligase ligand-linker conjugate, featuring a cereblon (CRBN)-based ligand linked to a suitable chemical moiety. This compound is pivotal for the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating selective protein degradation pathways. Its application in chemical biology research extends to targeted protein degradation and the investigation of novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-Piperazine-piperidine hydrochloride is a ligand-linker conjugate targeting E3 ligases, specifically designed for the synthesis of PROTAC (proteolysis-targeting chimera) compounds. This molecule features a CRBN-based ligand, facilitating targeted protein degradation for elucidating protein function and potential therapeutic applications. Its utility in drug discovery and development supports research in protein homeostasis and cellular regulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-Pip dihydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a CRBN-based ligand combined with a linker, facilitating the synthesis of PROTACs (Proteolysis Targeting Chimeras). It is suitable for research involving the modulation of protein levels in various biological pathways, providing valuable insights into cellular processes and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-Piperazine-piperidine dihydrochloride is a conjugate designed to target E3 ligases, specifically featuring a CRBN-based ligand and linker. This compound is instrumental in the synthesis of PROTACs, facilitating the targeted degradation of proteins in various research applications. It serves as a valuable tool for studying protein homeostasis and elucidating cellular mechanisms related to protein turnover.
